Dianthus Therapeutics, Inc.
A clinical-stage biotech developing antibody therapies for severe autoimmune diseases, Dianthus Therapeutics is built around its lead candidate, claseprubart, a selective C1s inhibitor designed for convenient subcutaneous self-injection and now in late-stage trials for conditions like generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. A second candidate, DNTH212, targets immune signals behind these diseases. The company holds worldwide development and commercial rights to its medicines outside Greater China.
10-Q · Quarter ended Jun 30, 2026 · SEC filing ↗
The Phase 3 CAPTIVATE trial in CIDP met its interim responder goal early, a milestone that moves claseprubart closer to a potential regulatory filing. was minimal at $0.8 million and the net loss widened to $50.2 million from $31.6 million a year ago, driven by an 85% increase in R&D expense to $48.7 million as the company advanced three late-stage trials. With $1.2 billion in cash after a March 2026 public offering, the company is funded into 2030 to see these programs through to data readouts.
Net loss widened to $50.2M in Q2 2026 as R&D spend nearly doubled to $48.7M, driven by advancing Phase 3 trials for lead candidate claseprubart.
We are a smaller reporting company, as defined by Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.
We are a smaller reporting company, as defined by Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.
Read original filing text →From time to time, we may be involved in litigation and other legal proceedings arising in the ordinary course of our business. We are not currently a party to or aware of any legal proceedings that we believe will have, individually or in the aggregate, a material adverse effec…
From time to time, we may be involved in litigation and other legal proceedings arising in the ordinary course of our business. We are not currently a party to or aware of any legal proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition, results of operations or cash flows. The outcome of any claims or litigation, regardless of the merits, is inherently uncertain. Regardless of the outcome, litigation and other legal proceedings can have a material adverse impact on us, our business, financial condition, results of operations or cash flows because of defense and settlement costs, diversion of management resources, in the case of intellectual property claims, requirements to change our product candidates, change our business practices, pay monetary damages or enter into short- or long-term royalty or licensing agreements, and other factors.
Read original filing text →You should carefully consider the risks, uncertainties and other factors contained in the risks factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, as well as the other information in this Quarterly Report on Form 10-Q, including our unaudit…
You should carefully consider the risks, uncertainties and other factors contained in the risks factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, as well as the other information in this Quarterly Report on Form 10-Q, including our unaudited condensed consolidated financial statements and related notes and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in our other public filings, in evaluating our business. The occurrence of any of the events or developments described in the above-mentioned risk factors could materially harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline. Additional risks, uncertainties and other factors not presently known to us or that we currently deem immaterial also may harm our business, financial condition, results of operations and growth prospects. 38
Read original filing text →